NEXGEL, Inc. (NXGL)
| Market Cap | 5.14M |
| Revenue (ttm) | 11.42M |
| Net Income (ttm) | -3.00M |
| Shares Out | 8.48M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,602 |
| Open | 0.607 |
| Previous Close | 0.607 |
| Day's Range | 0.590 - 0.618 |
| 52-Week Range | 0.560 - 2.968 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+230.03%) |
| Earnings Date | May 11, 2026 |
About NXGL
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure ... [Read more]
Financial Performance
In 2025, NEXGEL's revenue was $11.42 million, an increase of 31.46% compared to the previous year's $8.69 million. Losses were -$3.00 million, -8.56% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NXGL stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
NEXGEL Transcript: M&A announcement
The acquisition of Celularity's Degenerative Wound segment, backed by Sequence LifeScience, is expected to triple revenue, be immediately accretive, and transform the business into a diversified medical technology platform with strong growth prospects.
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
The transaction represents the most significant milestone in the company's history.
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off
NEXGEL Earnings Call Transcript: Q3 2025
Q3 2025 revenue was flat year-over-year at $2.9M, but gross margin improved to 42.4% and adjusted EBITDA loss narrowed. Strong contract manufacturing and new product launches are expected to drive a record Q4, with full-year revenue guidance of $12M–$12.5M.
NEXGEL Reports Third Quarter 2025 Financial Results
LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ult...
NEXGEL Transcript: LD Micro Main Event XIX Investor Conference
Significant growth achieved through strategic partnerships, acquisitions, and innovative hydrogel products. Expansion into new markets and product lines, strong revenue growth, and robust R&D pipeline position the company for continued success.
NEXGEL Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue double year-over-year to $2.9M, with gross margin rising to 43.6% and narrowing losses. Strong growth in both contract manufacturing and consumer products, expanded partnerships, and new product launches support reaffirmed 2025 guidance for $13M revenue and positive EBITDA.
NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL and STADA AG Announce Expansion of Partnership for North America
LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and...
NEXGEL Earnings Call Transcript: Q1 2025
Q1 2025 revenue surged 121% year-over-year to $2.81 million, with gross margin rebounding to 42.4%. Both contract manufacturing and consumer-branded products, especially Silly George, drove growth. 2025 guidance remains at $13 million revenue and cash flow positivity, with strong product pipeline and manageable tariff risks.
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL Transcript: Planet MicroCap Showcase: VEGAS 2025
Hydrogel technology drives growth across medical, consumer, and contract manufacturing divisions, with strong partnerships, product innovation, and expanding U.S. operations. Margin management and platform-specific marketing support continued revenue growth and a path to profitability.
NEXGEL Earnings Call Transcript: Q4 2024
Record revenue growth in 2024 was driven by strong performance in both branded consumer products and contract manufacturing, with new partnerships and product launches fueling expansion. Guidance for 2025 targets at least $13 million in revenue and positive EBITDA.
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa.
NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025
LANGHORNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Transcript: IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 2024
The presentation detailed strong revenue growth driven by new product launches, strategic acquisitions, and major partnerships, including nationwide distribution of SilverSeal and an upcoming supply deal with AbbVie. Expansion into new digital and retail platforms is planned, with a focus on achieving cash flow positivity.